Metastatic CRPC - no benefit from early Docetaxel chemo in Egyptian study

[JimmyToowong]

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

Tanta University Hospital, Tanta, Gharbia, Egypt.

abuhamar65@hotmail.com[1]This email address is being protected from spam bots, you need Javascript enabled to view it

Since previous studies have indicated there are improvements in overall survival, the aim of this phase II clinical study was to evaluate docetaxel every three weeks plus prednisone as first-line chemotherapy for treatment of hormone-refractory metastatic prostate cancer (HRMPC).

Thirty-five metastatic HRPC patients were treated with docetaxel 70 mg/m2 every 3 weeks plus oral prednisolone 5 mg twice daily at the clinical oncology departments of Tanta, Mansoura and Menofia university hospitals during the period from June 2006 to December 2008. The primary endpoint was assessment of the overall tumor response rate. Secondary endpoints were assessment of PSA response rate, overall survival rate, and the time-to-disease progression.

The median number of cycles administered was 6 cycles. Partial response was observed in 15 patients (42.9%) with evaluable measurable disease. Median survival from protocol entry was 15 months. Median time- to-disease progression was 10 months. Prostate-specific antigen (PSA) declined >50% in 9 patients (25.7%). The most common grade 3/4 toxicity associated with studied protocol was neutropenia (85.7%).

When given with prednisone, treatment with docetaxel every three weeks does not improve survival, so the benefit of docetaxel-based therapy is not clear this high risk and poor prognostic group of patients.

Written by:

Abu Hamar AM, Mansour S, El Shebiney M, El Bary NM, Sadaka E, Maria A. [2]

Reference: Hematol Oncol Stem Cell Ther. 2010;3(3):121-7

PMID: 20890069 Forum: Metastatic prostate cancer Title: Metastatic CRPC - no benefit from early Docetaxel chemo in Egyptian study

References

abuhamar65@hotmail.com

This extract can be found on http://PubMed.com, and is in the public domain.

On PubMed.com there will be a link to the full paper (often $30, sometimes free).

Any highlighting (except the title) is not by the author, but by Jim Marshall.

Jim is not a doctor.

This page was found on the Advanced Prostate Cancer Community for Australian men at http://advancedprost...lia.ipbhost.com.

The link is hard to remember.

An easier way to find it is to go to JimJimJimJim.com and click on Prostate.

That's the word Jim four times, no spaces, followed by .com.

If you need other help - to perhaps find someone to talk to or a local support group:

Click on the Contact Jim button at http://JimJimJimJim.com.